Efficacy of entecavir in decompensated postviral cirrhosis B
Versandkostenfrei!
Versandfertig in 6-10 Tagen
29,99 €
inkl. MwSt.
PAYBACK Punkte
15 °P sammeln!
Entecavir (ETV) is a potent nucleoside analogue recommended by learned societies as a first line treatment for B viral hepatopathy. The aim of our study was to investigate the efficacy of ETV in patients with post cirrhosis. -viral B decompensated.Methods: A comparative retrospective study was carried out which collected 66 patients with decompensated postviral B cirrhosis (31 patients treated with ETV and 35 untreated patients). The efficacy of ETV was evaluated via the virological response, the improvement liver function and the occurrence of cirrhosis complications. Results In the ETV group...
Entecavir (ETV) is a potent nucleoside analogue recommended by learned societies as a first line treatment for B viral hepatopathy. The aim of our study was to investigate the efficacy of ETV in patients with post cirrhosis. -viral B decompensated.Methods: A comparative retrospective study was carried out which collected 66 patients with decompensated postviral B cirrhosis (31 patients treated with ETV and 35 untreated patients). The efficacy of ETV was evaluated via the virological response, the improvement liver function and the occurrence of cirrhosis complications. Results In the ETV group (n=31), the virological response was 81% at 12 months. After 12 months of treatment, 38% of ETV-treated patients and 11% of untreated patients improved their Child score by 2 points. (p=0.04). Untreated patients developed significantly more de novo ascites (p=0.036) and more upper gastrointestinal bleeding (p=0.019). Conclusion: Our study showed that ETV-treated patients had a high rate ofvirological response, with improvement or stabilization of liver function.
Andere Kunden interessierten sich für
